Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – RARE

Core Viewpoint - A class action securities lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud affecting investors between August 3, 2023, and December 26, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx made misleading statements regarding the efficacy of setrusumab, particularly that while it increases bone density, it does not correlate with a decrease in annualized fracture rates [2] - On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing annualized clinical fracture rates compared to placebo or bisphosphonates [2] - Following this announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 6, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]